ANTIBODIES AGAINST SARS-CoV-2 SPIKE PROTEIN

• Main Authors: OMOTO SHINYA, NICOLAS CLAUDE PAUL SAX, KUROSAKI TOMOHIRO, NAKAGAWA TAKAYUKI, MORIYAMA AYANO, ADACHI YU, ONODERA HIROSHI, INOUE TAKESHI, SHINNAKASU RYO, ISHIKAWA MASAKAZU, TAKAHASHI YOSHIMASA, YAMASHITA KAZUO
• Format: Patent
• Language: English; Japanese
• Published: 19.12.2022
• Subjects: BEER; BIOCHEMISTRY; CHEMISTRY; COMPOSITIONS THEREOF; CULTURE MEDIA; ENZYMOLOGY; HUMAN NECESSITIES; HYGIENE; MEDICAL OR VETERINARY SCIENCE; METALLURGY; MICROBIOLOGY; MICROORGANISMS OR ENZYMES; MUTATION OR GENETIC ENGINEERING; ORGANIC CHEMISTRY; PEPTIDES; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS; SPIRITS; VINEGAR; WINE

To provide binding entities for the treatment, prevention, or diagnosis of coronavirus infection.SOLUTION: Provided is a binding entity comprising: any one of the heavy chain CDR1s set forth in any one of the COVID-19 consensus heavy chain CDR1 sequences I-VIII or SEQ ID NOs: 1 to 4, or a functionally equivalent sequence thereof; any one of the heavy chain CDR2s set forth in any one of the COVID-19 consensus heavy chain CDR2 sequences I-VIII or SEQ ID NOs:5 to 8, or a functionally equivalent sequence thereof; and/or any one of the heavy chain CDR3s set forth in any one of the COVID-19 consensus heavy chain CDR3 sequences I-XXX or SEQ ID NOs: 9 to12 or a functionally equivalent sequence thereof; as well as/or any one of the light chain CDR1s set forth in any one of the COVID-19 consensus light chain CDR1 sequences II-VIII or SEQ ID NOs: 17 to 20, or a functional equivalent sequence thereof; any one of the light chain CDR2s set forth in any one of the COVID-19 consensus light chain CDR2 sequences II-VIII or SEQ ID NOs: 21 to 24 or a functionally equivalent sequence thereof; and/or any one of the light chain CDR3s set forth in any one of the COVID-19 consensus light chain CDR3 sequences II-VIII or SEQ ID NOs:25 to 28 or a functionally equivalent sequence thereof.SELECTED DRAWING: None 【課題】 コロナウイルス感染症の治療、予防、または診断のための結合実体を提供すること。【解決手段】 ＣＯＶＩＤ－１９コンセンサス重鎖ＣＤＲ１配列Ｉ～ＶＩＩＩもしくは配列番号１～４のいずれか１つに記載の重鎖ＣＤＲ１もしくはその機能的等価配列のいずれか１つ、ＣＯＶＩＤ－１９コンセンサス重鎖ＣＤＲ２配列Ｉ～ＶＩＩＩもしくは配列番号５～８のいずれか１つに記載の重鎖ＣＤＲ２もしくはその機能的等価配列のいずれか１つ、および／またはＣＯＶＩＤ－１９コンセンサス重鎖ＣＤＲ３配列Ｉ～ＸＸＸもしくは配列番号９～１２のいずれか１つに記載の重鎖ＣＤＲ３もしくはその機能的等価配列のいずれか１つ、ならびに／またはＣＯＶＩＤ－１９コンセンサス軽鎖ＣＤＲ１配列ＩＩ～ＶＩＩＩもしくは配列番号１７～２０のいずれか１つに記載の軽鎖ＣＤＲ１もしくはその機能的等価配列のいずれか１つ、ＣＯＶＩＤ－１９コンセンサス軽鎖ＣＤＲ２配列ＩＩ～ＶＩＩＩもしくは配列番号２１～２４のいずれか１つに記載の軽鎖ＣＤＲ２もしくはその機能的等価配列のいずれか１つ、および／またはＣＯＶＩＤ－１９コンセンサス軽鎖ＣＤＲ３配列ＩＩ～ＶＩＩＩもしくは配列番号２５～２８のいずれか１つに記載の軽鎖ＣＤＲ３もしくはその機能的等価配列のいずれか１つ、を含む、結合実体。【選択図】 なし